Factors involved in early in vitro endotoxin hyporesponsiveness in human endotoxemia

Journal of Endotoxin Research

Volumn 3, Issue 4, 1996, Pages 283-289

  Kimmings, A Nikola ^a   Pajkrt, Dasja ^a   Zaaijer, Krista ^a   Moojen, Thybout M ^a   Meenan, John K ^a   Ten Cate, Jan W ^a   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; HYDROCORTISONE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; ENDOTOXEMIA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; SEPSIS;

EID: 0029791034     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Greisman S.E., Young E.J., Carozza Jr F.A. Mechanisms of endotoxin tolerance. V. Specificity of the early and late phases of pyrogenic tolerance. J Immunol 1969; 103: 1223-1236.
2. Greisman S.E., Hornick R.B., Carozza Jr F.A., Woodward T.E. The role of endotoxin during typhoid fever and tularemia in man. I. Acquisition of tolerance to endotoxin. J Clin Invest 1963; 42: 1064-1075.
3. Greisman S.E., Woodward T.E. Mechanisms of endotoxin tolerance. III. The refractory state during continuous intravenous infusions of endotoxin. J Exp Med 1965; 121: 911-933.
4. Greisman S.E., Hornick R.B. Mechanisms of endotoxin tolerance with special reference to man. J Infect Dis 1973; 128 (Suppl.): 265-276
5. Munoz C., Carlet J., Fitting C., Misset B., Biérot J.P., Cavaillon J.M. Dysregulation on in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88: 1747-1754.
6. Helminen M. Interleukin-1 production from peripheral blood monocytes in septic infections in children. Scand J Infect Dis 1991; 23: 607-611.
7. Simpson S.Q., Modi H.N., Balk R.A., Bone R.C., Casey L.C. Reduced alveolar macrophage production of tumor necrosis factor during sepsis in mice and men. Crit Care Med 1991; 19: 1060-1066.
8. Ayala A., Kisala J.M., Felt J.A., Perrin M.M., Chaudry I.H. Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis? Arch Surg 1992; 127: 191-197.
9. Johnston C.A., Greisman S.E. Mechanisms of endotoxin tolerance. Chapter 14. In: Hinshaw L.B. ed Handbook of Endotoxin, vol. 2, Pathophysiology of Endotoxin. Amsterdam: Elsevier, 1985; 359-399.
10. Rodrick M.L., Wood J.J., O'Mahony J.B. et al. Mechanisms of immunosuppression associated with severe nonthermal traumatic injuries in man: production of interleukin 1 and 2. J Clin Immunol 1986; 6: 310-318.
11. Greisman S.E., Young E.J., DuBuy B. Mechanism of endotoxin tolerance. VIII. Specificity of serum transfer. J Immunol 1973; 3: 1349-1360.
12. 51Cr-labeled lipid A before and after the induction of endotoxin tolerance. Proc Natl Acad Sci USA 1984; 81: 3491-3495.
13. Fahmi H., Chaby R. Desensitization of macrophages to endotoxin effects is not correlated with a downregulation of lipopolysaccharide-binding sites. Cell Immunol 1993; 150: 219-229.
14. McCall C.E., Grosso-Wilmoth L.M., LaRue K., Guzman R.N., Cousart S.L. Tolerance to endotoxin-induced expression of the interleukin-1β gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 1993; 91: 853-861.
15. Greisman S.E., Hornick R.B., Carozza F.A., Woodward T.E. Endotoxin tolerance. J Clin Invest 1964; 43: 986-999.
16. Zingarelli B., Makhlouf M., Halushka P.V., Caputi A.P., Cook J.A. Altered macrophage function in tumor necrosis factor-α and endotoxin-tolerance. J Endotoxin Res 1995; 2: 247-254.
17. Dentener M.A., Francot G.J.M., Smit F.T. et al. Presence of bactericidal/permeability increasing protein in disease; detection by ELISA. J Infect Dis 1995; 171: 739-743.
18. White M.L., Ma J.K., Birr C.A., Trown P.W., Carroll S.F. Measurement of bactericidal/permeability-increasing protein in human body fluids by sandwich ELISA. J Immunol Methods 1994; 167: 227-237.
19. van de Poll T., Jansen J., van Leenen D. et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168: 955-960.
20. van de Poll T., Jansen J., Levi M., ten Cate H., ten Cate J.W., van Deventer S.J.H. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med 1994; 180: 1985-1988.
21. Engelberts I., Moller A., Schoen G.J.M., van der Linden C.J., Buurman W.A. Evaluation of measurement of human TNF in plasma by ELISA. Lympnokine Res 1991; 10: 69-76.
22. Bruin K.F., von der Möhlen M.A.M., Jansen J., Prins M.H., ten Cate J.W., van Deventer S.J.H. Septic serum inhibits endotoxin-induced tumor necrosis factor release by human peripheral blood mononuclear cells. In: Thesis: Endotoxin Responsiveness in Humans. Amsterdam: Thesis Publishers, 1994; 78-92.
23. 23). J Infect Dis 1995; 172: 144-151.
24. Rodrick M.L., Moss N.M., Grbic J.T. et al. Effects of in vivo endotoxin infusions on in vitro cellular immune responses in humans. J Clin Immunol 1992, 12: 440-450.
25. Olofsson P., Olofsson C., Nylander G., Olsson P. Endotoxin inactivation in plasma from septic patients: an in vitro study. World J Surg 1986; 10: 318-323.
26. Ulevitch R.J., Johnston A.R. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum. J Clin Invest 1978; 62: 1313-1324.
27. Granowitz E.V., Porat R., Mier J.W. et al. Intravenous endotoxin suppresses the cytokine response of periferal blood mononuclear cells of healthy humans. J Immunol 1993; 151: 1637-1645.
28. Haas J.G., Thiel C., Blomer K., Weiss E.H., Riethmüller G., Ziegler-Heitbrock H.W.L. Downregulation of tumor necrosis factor expression in the human Mono-Mac-6 cell line by lipopolysaccharide. J Leukocyte Biol 1989; 46: 11-14.
29. Ziegler-Heitbrock H.W., Blumenstein M., Kafferlein E. et al. In vitro desensitization to lipopolysaccharide suppresses tumor necrosis factor, interleukin-1 and interleukin-6 gene expression in a similar fashion. Immunology 1992; 75: 264-268.
30. Haas J.G., Baeuerle P.A., Riethmüller G., Ziegler-Heitbrock H.W.L. Molecular mechanism in down-regulation of tumor necrosis factor expression. Proc Natl Acad Sci USA 1990; 87: 9563-9567.
31. Takasuka N., Tokunaga T., Akagawa K.S. Preexposure of macrophages to low doses of lipopolysaccharide inhibits the expression of tumor necrosis factor-α mRNA but not of IL-1β mRNA. J Immunol 1991; 146: 3824-3830.
32. Granowitz E.V., Santos A.A., Poutsiaka D.D. et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991; 338: 1423-1424.
33. Henricson B.E., Neta R., Vogel S.N. An interleukin-1 receptor antagonist blocks lipopolysaccharide-induced colony-stimulating factor production and early endotoxin tolerance. Infect Immun 1991; 59: 1188-1191.
34. de Waal-Malefyt R., Abrams R.J., Bennett B., Figdor C.G., de Vries J. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174; 1209-1220.
35. Florentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815-3822.
36. Gerard C., Bruyns C., Marchant A. et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177: 547-550.
37. Berg D.J., Kühn R., Rajewski K. et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995; 96: 2339-2347.
38. Marra M.N., Wilde C.G., Collins M.S., Snable J.L., Thornton M.B., Scott R.W. The role of bactericidal/permeability increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 1992; 148: 532-537.
39. Cupps T.R., Fauci A.S. Corticosteroid-mediated immunoregulation in man. Immunol Rev 1982; 65: 133-155.
40. Tanigushi T. Regulation of cytokine gene expression Annu Rev Immunol 1988; 6: 439-464.